Aesthetics & Anti-Aging · Reviewed by Ian K. Tseng, MD

What Is GHK-Cu? The Copper Peptide, Topical and Otherwise

GHK-Cu is unusual among the compounds in this space because it has a substantial presence in two very different worlds: it is a well-established cosmetic skincare ingredient sold over the counter, and it has also been prepared as a compounded injectable — a route that currently has no 503A compounding pathway. The evidence supporting those two uses is not equally strong, and conflating them is the most common mistake in how this compound gets discussed.

Published August 4, 2026 · Medical review by Ian K. Tseng, MD, Medical Director

Amber pharmacy vial labelled GHK-Cu on warm marble, illustrating a aesthetics & anti-aging compound discussed in this educational article

The short answer

GHK-Cu is a naturally occurring tripeptide — glycyl-L-histidyl-L-lysine — bound to a copper ion. It is present in human plasma, saliva, and urine, and plasma concentration declines substantially with age. Research has examined roles in wound healing, collagen and elastin synthesis, and antioxidant activity. The strongest evidence relates to topical application. Injectable GHK-Cu is less extensively studied, is not FDA-approved, and under current federal rules is not available through 503A compounding pharmacies.

A peptide your body already carries

GHK is a three-amino-acid sequence — glycine, histidine, lysine — with a strong natural affinity for copper. In the body it exists predominantly bound to copper as GHK-Cu, and it is found in plasma, saliva, and urine.

The frequently cited observation is the age-related decline: plasma GHK concentration is roughly 200 nanograms per milliliter around age twenty and falls to approximately 80 by age sixty. That decline correlates with the period during which skin regenerative capacity and wound-healing speed also decline, which is the origin of the interest in the compound.

Correlation is doing real work in that sentence, and it should be read as the reason the research was pursued rather than as the conclusion of it.

Plasma GHK concentration falls with age

Approximate reported plasma concentration

Around age 20~200 ng/mL

Around age 60~80 ng/mL

Two reported reference points, not a measured curve. The decline parallels the period in which skin regenerative capacity and wound-healing speed also fall — which is why the research was pursued, not a conclusion of it.

What the topical research supports

The best-developed evidence for GHK-Cu concerns topical application to skin. Studies have examined effects on collagen and elastin synthesis, glycosaminoglycan production, skin firmness and elasticity measures, and wound repair. This is why copper peptides appear as a named active ingredient across a wide range of serums and creams — the cosmetic use rests on a real literature.

Because topical GHK-Cu is a cosmetic ingredient rather than a drug, it does not require a prescription and its claims are cosmetic claims. Our article on topical versus injectable peptides explains why delivery route changes both the regulatory category and the physiological reality of what reaches which tissue.

Injectable preparations are a different question

Injectable GHK-Cu has not been through FDA pre-market review, and under current federal rules it has no pathway for 503A compounding: it was removed from the FDA’s Category 2 list in April 2026 but has not been added to the 503A bulks list. The human clinical literature supporting systemic administration is considerably thinner than the topical dermatologic literature.

This is worth stating plainly because the marketing frequently borrows credibility across the boundary — citing topical skin studies in support of an injectable protocol. Those are different exposures, different tissue concentrations, and different evidence bases. The topical research does not settle the injectable question.

The same molecule, two very different evidence bases

Topical (cosmetic)

The better-developed literature

Studied for collagen and elastin synthesis
Glycosaminoglycan production and wound repair
Measures of skin firmness and elasticity
Sold over the counter; cosmetic claims, no prescription

Injectable

A separate question

No current 503A compounding pathway under federal rules
Not reviewed by the FDA in that form
Considerably thinner human clinical literature
Different exposure and tissue concentration entirely

Marketing frequently borrows credibility across this boundary — citing topical skin studies in support of an injectable protocol. Topical research does not settle the injectable question.

Topical copper peptides and in-office skin treatments

Topical copper-peptide skincare is often used alongside in-office treatments like RF microneedling and IPL, which act locally on the skin through entirely different mechanisms. Whether and when to use an active topical around a specific treatment is a question for the provider performing it.

Frequently asked questions

What is GHK-Cu?

A naturally occurring tripeptide — glycyl-L-histidyl-L-lysine — bound to a copper ion. It is present in human plasma, saliva, and urine. Plasma concentration is roughly 200 nanograms per milliliter around age twenty and declines to approximately 80 by age sixty, a decline that parallels reductions in skin regenerative capacity.

Are copper peptides in skincare the same as injectable GHK-Cu?

They are the same molecule delivered by fundamentally different routes, with different evidence bases and different regulatory categories. Topical GHK-Cu is a cosmetic ingredient with a well-developed dermatologic literature on collagen and elastin synthesis and skin firmness. Injectable GHK-Cu is not FDA-approved, currently has no 503A compounding pathway, and has considerably thinner human clinical literature. Topical research does not establish injectable outcomes.

What does the topical GHK-Cu research show?

Studies have examined effects on collagen and elastin synthesis, glycosaminoglycan production, measures of skin firmness and elasticity, and wound repair. This literature is the basis for copper peptides appearing as a named active ingredient in cosmetic serums and creams. As a cosmetic ingredient it does not require a prescription, and its claims are cosmetic rather than medical claims.

Can GHK-Cu be combined with in-office aesthetic treatments?

Topical copper-peptide skincare is often used alongside device-based treatments such as RF microneedling and IPL, which act on the skin through entirely different mechanisms. Whether and when to use an active topical around a specific treatment is a question for the provider performing it. Injectable GHK-Cu is not currently available through 503A compounding pharmacies under federal rules.

Clinical references

Medically reviewed by Ian K. Tseng, MD, Medical Director of Soothe IV's peptide therapy program. The clinical statements in this article are supported by the following sources:

Pickart L, Margolina A. Regenerative and Protective Actions of the GHK-Cu Peptide in the Light of the New Gene Data. International Journal of Molecular Sciences. 2018. pmc.ncbi.nlm.nih.gov
Pickart L, Vasquez-Soltero JM, Margolina A. GHK Peptide as a Natural Modulator of Multiple Cellular Pathways in Skin Regeneration. BioMed Research International. 2015. pmc.ncbi.nlm.nih.gov
U.S. Food & Drug Administration. Human Drug Compounding. www.fda.gov

Explore our telehealth programs

Our telehealth wellness programs start with an intake and an evaluation by a clinician licensed in your state, with ongoing oversight from our licensed medical team, directed by Medical Director Ian K. Tseng, MD. What is clinically appropriate depends entirely on that evaluation, and not everyone qualifies. Available in 47 states + D.C.

See our programs

Serving Orange County, Los Angeles, and San Diego — plus telehealth in 47 states + D.C. All service areas.

This article is educational and is not medical advice. Statements have not been evaluated by the FDA. Peptide therapy is a physician-supervised medical service; specific protocols are determined individually after a Good Faith Examination and bloodwork, and not all applicants qualify. Some compounded medications used in physician-prescribed protocols are not FDA-approved. Data from clinical trials on FDA-approved medications should not be used to make assessments related to compounded medications. Soothe IV's peptide program is available via telehealth in 47 states and Washington, D.C. (every state except Alabama, Alaska and Mississippi); prescriptions are issued by clinicians licensed in your state.